Literature DB >> 9309666

Rapid isolation of muscle and heart mitochondria, the lability of oxidative phosphorylation and attempts to stabilize the process in vitro by taurine, carnitine and other compounds.

H R Scholte1, Y Yu, J D Ross, I I Oosterkamp, A M Boonman, H F Busch.   

Abstract

We modified the isolation procedure of muscle and heart mitochondria. In human muscle, this resulted in a 3.4 fold higher yield of better coupled mitochondria in half the isolation time. In a preparation from rat muscle we studied factors that affected the stability of oxidative phosphorylation (oxphos) and found that it decreased by shaking the preparation on a Vortex machine, by exposure to light and by an increase in storage temperature. The decay was found to be different for each substrate tested. The oxidation of ascorbate was most stable and less sensitive to the treatments. When mitochondria were stored in the dark and the cold, the decrease in oxidative phosphorylation followed first order kinetics. In individual preparations of muscle and heart mitochondria, protection of oxidative phosphorylation was found by adding candidate stabilizers, such as desferrioxamine, lazaroids, taurine, carnitine, phosphocreatine, N-acetylcysteine. Trolox-C and ruthenium red, implying a role for reactive oxygen species and calcium-ions in the in vitro damage at low temperature to oxidative phosphorylation. In heart mitochondria oxphos with pyruvate and palmitoylcarnitine was most labile followed by glutamate, succinate and ascorbate. We studied the effect of taurine, hypotaurine, carnitine, and desferrioxamine on the decay of oxphos with these substrates. 1 mM taurine (n = 6) caused a significant protection of oxphos with pyruvate, glutamate and palmitoylcarnitine, but not with the other substrates. 5 mM L-carnitine (n = 6), 1 mM hypotaurine (n = 3) and 0.1 mM desferrioxamine (n = 3) did not protect oxphos with any of the substrates at a significant level. These experiments were undertaken in the hope that the in vitro stabilizers can be used in future treatment of patients with defects in oxidative phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309666

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  21 in total

1.  MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin.

Authors:  A M Penn; J W Lee; P Thuillier; M Wagner; K M Maclure; M R Menard; L D Hall; N G Kennaway
Journal:  Neurology       Date:  1992-11       Impact factor: 9.910

2.  Reproducibility of differential centrifugation experiments in tissue fractionation.

Authors:  C DE DUVE; J BERTHET
Journal:  Nature       Date:  1953-12-19       Impact factor: 49.962

3.  A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study.

Authors:  R LUFT; D IKKOS; G PALMIERI; L ERNSTER; B AFZELIUS
Journal:  J Clin Invest       Date:  1962-09       Impact factor: 14.808

4.  The treatment of mitochondrial myopathies and encephalomyopathies.

Authors:  P L Peterson
Journal:  Biochim Biophys Acta       Date:  1995-05-24

5.  Construction and performance of a new catheter-tip oxygen electrode.

Authors:  T C Jansen; H N Lafeber; H K Visser; G Kwant; B Oeseburg; W G Zijlstra
Journal:  Med Biol Eng Comput       Date:  1978-05       Impact factor: 2.602

6.  Antioxidant action of lazaroids.

Authors:  E D Hall; J M McCall
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

7.  Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.

Authors:  P Cianciulli; D Sollecito; F Sorrentino; L Forte; E Gilardi; A Massa; G Papa; S Carta
Journal:  Kidney Int       Date:  1994-08       Impact factor: 10.612

8.  Stabilising action of carnitine on energy linked processes in rat liver mitochondria.

Authors:  F Di Lisa; V Bobyleva-Guarriero; P Jocelyn; A Toninello; N Siliprandi
Journal:  Biochem Biophys Res Commun       Date:  1985-09-16       Impact factor: 3.575

9.  Riboflavin-responsive complex I deficiency.

Authors:  H R Scholte; H F Busch; H D Bakker; J M Bogaard; I E Luyt-Houwen; L P Kuyt
Journal:  Biochim Biophys Acta       Date:  1995-05-24

10.  Novel 21-aminosteroidlike compounds prevent iron-induced free radical-mediated injury to vascular endothelial cells.

Authors:  R Pakala; R Pakala; C R Benedict
Journal:  J Cardiovasc Pharmacol       Date:  1995-06       Impact factor: 3.105

View more
  12 in total

1.  Human quadriceps muscle mitochondria: a functional characterization.

Authors:  U F Rasmussen; H N Rasmussen
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  A truncated progesterone receptor (PR-M) localizes to the mitochondrion and controls cellular respiration.

Authors:  Qunsheng Dai; Anish A Shah; Rachana V Garde; Bryan A Yonish; Li Zhang; Neil A Medvitz; Sara E Miller; Elizabeth L Hansen; Carrie N Dunn; Thomas M Price
Journal:  Mol Endocrinol       Date:  2013-03-21

3.  High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders.

Authors:  W Sperl; D Skladal; E Gnaiger; M Wyss; U Mayr; J Hager; F N Gellerich
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

Review 4.  Energetic depression caused by mitochondrial dysfunction.

Authors:  Frank Norbert Gellerich; Sonata Trumbeckaite; Tobias Müller; Marcus Deschauer; Ying Chen; Zemfira Gizatullina; Stephan Zierz
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

5.  A role for taurine in mitochondrial function.

Authors:  Svend Høime Hansen; Mogens Larsen Andersen; Claus Cornett; Robert Gradinaru; Niels Grunnet
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

6.  Taurine supplementation increases skeletal muscle force production and protects muscle function during and after high-frequency in vitro stimulation.

Authors:  Craig A Goodman; Deanna Horvath; Christos Stathis; Trevor Mori; Kevin Croft; Robyn M Murphy; Alan Hayes
Journal:  J Appl Physiol (1985)       Date:  2009-05-07

7.  Nine months of combined training improves ex vivo skeletal muscle metabolism in individuals with type 2 diabetes.

Authors:  Lauren M Sparks; Neil M Johannsen; Timothy S Church; Conrad P Earnest; Esther Moonen-Kornips; Cedric Moro; Matthijs K C Hesselink; Steven R Smith; Patrick Schrauwen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-05       Impact factor: 5.958

8.  The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice.

Authors:  W Wallace Harrington; Christy S Britt; Joan G Wilson; Naphtali O Milliken; Jane G Binz; David C Lobe; William R Oliver; Michael C Lewis; Diane M Ignar
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

9.  Regulation of muscle fiber type and running endurance by PPARdelta.

Authors:  Yong-Xu Wang; Chun-Li Zhang; Ruth T Yu; Helen K Cho; Michael C Nelson; Corinne R Bayuga-Ocampo; Jungyeob Ham; Heonjoong Kang; Ronald M Evans
Journal:  PLoS Biol       Date:  2004-08-24       Impact factor: 8.029

10.  The Responses of Tissues from the Brain, Heart, Kidney, and Liver to Resuscitation following Prolonged Cardiac Arrest by Examining Mitochondrial Respiration in Rats.

Authors:  Junhwan Kim; José Paul Perales Villarroel; Wei Zhang; Tai Yin; Koichiro Shinozaki; Angela Hong; Joshua W Lampe; Lance B Becker
Journal:  Oxid Med Cell Longev       Date:  2015-12-07       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.